Lionco Pharmaceutical Group Co., Ltd. Class ASSE: 603669

"Lionco Pharmaceutical Group Co., Ltd."Announcement on Obtaining Drug Registration Certificate for Isavuconazonium Sulfate for Injection by Wholly-owned Subsidiary

Sep 30, 2026 · Issued by Lionco Pharmaceutical Group Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Obtaining Drug Registration Certificate for Isavuconazonium Sulfate for Injection by Wholly-owned Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Lionco Pharmaceutical Group Co., Ltd. Class A

"Lionco Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026Sep 17
"Lionco Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 12th Meeting of the 5th Board of DirectorsSep 1
"Lionco Pharmaceutical Group Co., Ltd."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026Aug 15
"Lionco Pharmaceutical Group Co., Ltd."Announcement on Selection of the Subsidiary's Product Huperzine A for Injection in the Inter-Provincial Alliance Centralized ProcurementAug 13

All Lionco Pharmaceutical Group Co., Ltd. Class A news releases